Latest thyroid cancer Stories
WOODCLIFF LAKE, N.J., Oct. 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that the U.S.
Launched in Conjunction with Thyroid Cancer Awareness Month, aMTCSupport.com Offers Resources and Support for Rare Disease Community WILMINGTON, Del., Sept.
Tokyo, Sept 17, 2014 - (JCN Newswire) - Eisai Co., Ltd.
The Firm is evaluating Byetta lawsuits on behalf of individuals who developed pancreatitis, pancreatic cancer or thyroid cancer allegedly due to their use of Byetta or other incretin mimetic Type
The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer due to their use of the medication. New
-- 2Q Revenue Increased 71%, Compared to Prior Year -- SOUTH SAN FRANCISCO, Calif., Aug.
Transaction Marks First Step Toward Creation of a Molecular Diagnostics Subsidiary to Aid in Patient Diagnosis and Management PARSIPPANY, N.J., Aug. 13, 2014 /PRNewswire/ -- PDI, Inc.
The Firm is investigating Byetta lawsuits and other legal claims that allege incretin mimetics like Byetta, Januvia and Victoza caused patients to develop pancreatic cancer, pancreatitis or thyroid
The routine use of a molecular testing panel developed at UPMC greatly increases the likelihood of performing the correct initial surgery for patients with thyroid nodules and cancer, report researchers
-- Nexavar is the only approved treatment for patients with RAI-refractory differentiated thyroid cancer -- Nexavar significantly extended progression-free survival
- Large; stout; burly.